State Street SPDR S&P Biotech ETF
199 hedge funds and large institutions have $3.15B invested in State Street SPDR S&P Biotech ETF in 2015 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 51 increasing their positions, 71 reducing their positions, and 29 closing their positions.
28% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 29
2% more funds holding
Funds holding: 196 → 199 (+3)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less capital invested
Capital invested by funds: $3.25B → $3.15B (-$99M)
22.59% less ownership
Funds ownership: 159.26% → 136.68% (-23%)
28% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 71
59% less call options, than puts
Call options by funds: $490M | Put options by funds: $1.2B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$58.5M |
| 2 |
Morgan Stanley
New York
|
+$43M |
| 3 |
LPL Financial
San Diego,
California
|
+$17.1M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$14.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$391M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$48.3M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$38.1M |
| 4 |
SG Americas Securities
New York
|
-$34.2M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$28.5M |
XBI Hedge Fund Activity: Q4 2015 in Review
199 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2015, worth a combined $3.15B — down 3% from $3.25B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new XBI positions and 29 closed out — a net gain of 8 holders — while 51 added to existing stakes and 71 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $58.5M. The largest seller was Goldman Sachs, cutting an estimated $391M.
- 199 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2015, up from 196 in Q3 2015.
- Funds reported $3.15B of State Street SPDR S&P Biotech ETF stock for Q4 2015, down 3% quarter-over-quarter.
- 37 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2015 and 29 closed out, a net change of +8 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q4 2015 was BNP Paribas Financial Markets, an estimated $58.5M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q4 2015 was Goldman Sachs, an estimated $391M sold.
Based on aggregated 13F filings for Q4 2015.